ARTBIO Strengthens Alpha Radioligand Therapy Programs With Senior Nuclear Metrology Hire

According to a recent LinkedIn post from ARTBIO, the company is adding Denis Bergeron as Senior Director of Nuclear Metrology, signaling a strengthening of its technical leadership in alpha radioligand therapy (ART) clinical programs. The post notes that Bergeron previously spent 18 years in the Radioactivity Group at the U.S. National Institute of Standards and Technology, and has held editorial and professional roles in nuclear medicine.

The post suggests ARTBIO is investing in metrology expertise to support the precision, safety and regulatory rigor required for advanced radiopharmaceutical development. For investors, this type of senior hire may indicate continued progression toward clinical execution, potentially improving ARTBIO’s positioning in the competitive alpha radioligand therapy space and supporting future partnership or funding discussions.